Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 155

1.

The androgen receptor antagonist enzalutamide induces apoptosis, dysregulates the heat shock protein system, and diminishes the androgen receptor and estrogen receptor β1 expression in prostate cancer cells.

Abazid A, Martin B, Choinowski A, McNeill RV, Brandenburg LO, Ziegler P, Zimmermann U, Burchardt M, Erb H, Stope MB.

J Cell Biochem. 2019 Oct;120(10):16711-16722. doi: 10.1002/jcb.28929. Epub 2019 Jul 11.

PMID:
31297844
2.

Corrigendum to "Generation of human induced pluripotent stem cell lines (hiPSC) from one bipolar disorder patient carrier of a DGKH risk haplotype and one non-risk-variant-carrier bipolar disorder patient" [Stem Cell Res. 2018 Oct;32:104-109. doi: 10.1016/j.scr.2018.09.008. Epub 2018 Sep 17].

Palladino VS, Subrata NOC, Geburtig-Chiocchetti A, McNeill R, Hoffmann P, Reif A, Kittel-Schneider S.

Stem Cell Res. 2019 Apr;36:101419. doi: 10.1016/j.scr.2019.101419. Epub 2019 Mar 18. No abstract available.

3.

Specificity of the Metallothionein-1 Response by Cadmium-Exposed Normal Human Urothelial Cells.

McNeill RV, Mason AS, Hodson ME, Catto JWF, Southgate J.

Int J Mol Sci. 2019 Mar 17;20(6). pii: E1344. doi: 10.3390/ijms20061344.

4.

Genetic risk factors and gene-environment interactions in adult and childhood attention-deficit/hyperactivity disorder.

Palladino VS, McNeill R, Reif A, Kittel-Schneider S.

Psychiatr Genet. 2019 Jun;29(3):63-78. doi: 10.1097/YPG.0000000000000220. Review.

PMID:
30741787
5.

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.

Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde AM, Sabatine MS; DECLARE–TIMI 58 Investigators.

N Engl J Med. 2019 Jan 24;380(4):347-357. doi: 10.1056/NEJMoa1812389. Epub 2018 Nov 10.

PMID:
30415602
6.

Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial.

Bohula EA, Scirica BM, Inzucchi SE, McGuire DK, Keech AC, Smith SR, Kanevsky E, Murphy SA, Leiter LA, Dwyer JP, Corbalan R, Hamm C, Kaplan L, Nicolau JC, Ophuis TO, Ray KK, Ruda M, Spinar J, Patel T, Miao W, Perdomo C, Francis B, Dhadda S, Bonaca MP, Ruff CT, Sabatine MS, Wiviott SD; CAMELLIA-TIMI 61 Steering Committee Investigators.

Lancet. 2018 Nov 24;392(10161):2269-2279. doi: 10.1016/S0140-6736(18)32328-6. Epub 2018 Oct 4.

7.

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial.

Hernandez AF, Green JB, Janmohamed S, D'Agostino RB Sr, Granger CB, Jones NP, Leiter LA, Rosenberg AE, Sigmon KN, Somerville MC, Thorpe KM, McMurray JJV, Del Prato S; Harmony Outcomes committees and investigators.

Lancet. 2018 Oct 27;392(10157):1519-1529. doi: 10.1016/S0140-6736(18)32261-X. Epub 2018 Oct 2.

PMID:
30291013
8.

Generation of human induced pluripotent stem cell lines (hiPSC) from one bipolar disorder patient carrier of a DGKH risk haplotype and one non-risk-variant-carrier bipolar disorder patient.

Palladino VS, Subrata NOC, Geburtig-Chiocchetti A, McNeill R, Hoffmann P, Reif A, Kittel-Schneider S.

Stem Cell Res. 2018 Oct;32:104-109. doi: 10.1016/j.scr.2018.09.008. Epub 2018 Sep 17. Erratum in: Stem Cell Res. 2019 Apr;36:101419.

9.

Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients.

Bohula EA, Wiviott SD, McGuire DK, Inzucchi SE, Kuder J, Im K, Fanola CL, Qamar A, Brown C, Budaj A, Garcia-Castillo A, Gupta M, Leiter LA, Weissman NJ, White HD, Patel T, Francis B, Miao W, Perdomo C, Dhadda S, Bonaca MP, Ruff CT, Keech AC, Smith SR, Sabatine MS, Scirica BM; CAMELLIA–TIMI 61 Steering Committee and Investigators.

N Engl J Med. 2018 Sep 20;379(12):1107-1117. doi: 10.1056/NEJMoa1808721. Epub 2018 Aug 26.

10.

A randomised controlled trial of patient information leaflets as a medication counselling aid.

McNeill R, Chin P, Coberger E, Doogue M.

Intern Med J. 2019 Mar;49(3):328-332. doi: 10.1111/imj.14038.

PMID:
30022574
11.

PIK3CA missense mutations promote glioblastoma pathogenesis, but do not enhance targeted PI3K inhibition.

McNeill RS, Stroobant EE, Smithberger E, Canoutas DA, Butler MK, Shelton AK, Patel SD, Limas JC, Skinner KR, Bash RE, Schmid RS, Miller CR.

PLoS One. 2018 Jul 5;13(7):e0200014. doi: 10.1371/journal.pone.0200014. eCollection 2018.

12.

Federal, provincial and territorial public health response plan for biological events.

McNeill R, Topping J; FPT Response Plan Task Group.

Can Commun Dis Rep. 2018 Jan 4;44(1):1-5. eCollection 2018 Jan 4.

13.

National Costs Associated With Methicillin-Susceptible and Methicillin-Resistant Staphylococcus aureus Hospitalizations in the United States, 2010-2014.

Klein EY, Jiang W, Mojica N, Tseng KK, McNeill R, Cosgrove SE, Perl TM.

Clin Infect Dis. 2019 Jan 1;68(1):22-28. doi: 10.1093/cid/ciy399.

14.

Modifiable risk factors for prescription medicine sharing behaviours.

Beyene K, Aspden T, McNeill R, Sheridan J.

Res Social Adm Pharm. 2019 Feb;15(2):154-163. doi: 10.1016/j.sapharm.2018.04.005. Epub 2018 Apr 6.

PMID:
29680636
15.

A framework for increasing the availability of life cycle inventory data based on the role of multinational companies.

Miah JH, Griffiths A, McNeill R, Halvorson S, Schenker U, Espinoza-Orias N, Morse S, Yang A, Sadhukhan J.

Int J Life Cycle Assess. 2018;23(9):1744-1760. doi: 10.1007/s11367-017-1391-y. Epub 2017 Oct 4.

16.

Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.

Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, Chan JC, Choi J, Gustavson SM, Iqbal N, Maggioni AP, Marso SP, Öhman P, Pagidipati NJ, Poulter N, Ramachandran A, Zinman B, Hernandez AF; EXSCEL Study Group.

N Engl J Med. 2017 Sep 28;377(13):1228-1239. doi: 10.1056/NEJMoa1612917. Epub 2017 Sep 14.

17.

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.

Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker SD, Kastelein JJP, Cornel JH, Pais P, Pella D, Genest J, Cifkova R, Lorenzatti A, Forster T, Kobalava Z, Vida-Simiti L, Flather M, Shimokawa H, Ogawa H, Dellborg M, Rossi PRF, Troquay RPT, Libby P, Glynn RJ; CANTOS Trial Group.

N Engl J Med. 2017 Sep 21;377(12):1119-1131. doi: 10.1056/NEJMoa1707914. Epub 2017 Aug 27.

18.

The immunosuppressive cytokine interleukin-4 increases the clonogenic potential of prostate stem-like cells by activation of STAT6 signalling.

Nappo G, Handle F, Santer FR, McNeill RV, Seed RI, Collins AT, Morrone G, Culig Z, Maitland NJ, Erb HHH.

Oncogenesis. 2017 May 29;6(5):e342. doi: 10.1038/oncsis.2017.23.

19.

Combined kinase inhibitors of MEK1/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancer.

Van Swearingen AED, Sambade MJ, Siegel MB, Sud S, McNeill RS, Bevill SM, Chen X, Bash RE, Mounsey L, Golitz BT, Santos C, Deal A, Parker JS, Rashid N, Miller CR, Johnson GL, Anders CK.

Neuro Oncol. 2017 Oct 19;19(11):1481-1493. doi: 10.1093/neuonc/nox052.

20.

Genomic profiles of low-grade murine gliomas evolve during progression to glioblastoma.

Vitucci M, Irvin DM, McNeill RS, Schmid RS, Simon JM, Dhruv HD, Siegel MB, Werneke AM, Bash RE, Kim S, Berens ME, Miller CR.

Neuro Oncol. 2017 Sep 1;19(9):1237-1247. doi: 10.1093/neuonc/nox050.

Supplemental Content

Loading ...
Support Center